Triple Negative Breast CancerPhase 3ASCENT-04NCT05382286
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
A Phase 3 study testing Sacituzumab Govitecan-hziy, Pembrolizumab and Paclitaxel in people with Triple Negative Breast Cancer and PD-L1 Positive, run by Gilead Sciences at 504 sites in 28 countries.
Trial summary
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's choice (TPC) and pembrolizumab in participants with previously untreated, locally advanced inoperable or metastatic triple-negative breast… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Triple Negative Breast Cancer, PD-L1 Positive
- What is being tested?
- Sacituzumab Govitecan-hziy, Pembrolizumab and Paclitaxel
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 443 participants
- Where
- 504 sitesin 28 countries
- Study dates
- 25 Jul 2022to Feb 2027
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Individuals with locally advanced, inoperable, or metastatic triple-negative breast cancer (TNBC) who have not received previous systemic therapy for advanced disease and whose tumors are programmed cell death ligand 1 (PD-L1) positive at screening.
- Individuals must have completed treatment for Stage I to III breast cancer, if indicated, and ≥ 6 months must have elapsed between completion of treatment with curative intent and first documented local or distant disease recurrence.
- Individuals presenting with de novo metastatic TNBC are eligible for this study.
- TNBC status and tumor PD-L1 combined positive score (CPS) will be confirmed centrally on a recent or archival tumor specimen.
- Individuals must have measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) as per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria as evaluated locally.
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
Show all 9Show fewer
- Demonstrates adequate organ function
- Male and female individuals of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception.
- Individuals with HIV must be on antiretroviral therapy (ART) and have a well-controlled HIV infection/disease.
Who cannot join
- Positive serum pregnancy test or women who are lactating.
- Received prior therapy with an agent directed to another stimulatory or coinhibitory T-cell receptor.
- Individuals may not have received systemic anticancer treatment (with the exception of endocrine therapy) within the previous 6 months or radiation therapy within 2 weeks prior to enrollment.
- Individuals may not be participating in a study with an investigational agent or investigational device within 4 weeks prior to randomization. Individuals participating in observational studies are eligible.
- Have previously received topoisomerase 1 inhibitors or antibody drug conjugates containing a topoisomerase inhibitor.
- Have an active second malignancy.
Show all 11Show fewer
- Have active serious infection requiring antibiotics.
- Individuals positive for HIV-1 or 2 with a history of Kaposi sarcoma and/or Multicentric Castleman Disease.
- Have active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
- Has an active autoimmune disease that has required systemic treatment in the past 2 years.
- Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Trial locations and contacts
504 sites in 28 countries.
504 sites in 28 countries
United States247 sites
Advent Health Medical Group
Altamonte Springs, Florida, 32701
SCRI - Florida Cancer Specialists - North Region R,750 Orienta Ave
Altamonte Springs, Florida, 32701
Alaska Oncology and Hematology
Anchorage, Alaska, 99508
University of Michigan
Ann Arbor, Michigan, 48109
The Center for Cancer and Blood Disorders - Magnolia,515 W. Mayfield Rd.
Arlington, Texas, 76104
Northside Hospital,125 King Avenue
Athens, Georgia, 30606
Piedmont Cancer Institute - Atlanta,1267 Hwy 54W
Atlanta, Georgia, 30214
Winship Cancer Institute of Emory University,550 Peachtree St NE
Atlanta, Georgia, 30308
Piedmont Cancer Institute - Atlanta
Atlanta, Georgia, 30318
Winship Cancer Institute of Emory University
Atlanta, Georgia, 30322
Northside Hospital,5670 Peachtree Dunwoody Rd.
Atlanta, Georgia, 30342
Northside Hospital
Atlanta, Georgia, 30342
Winship Cancer Institute of Emory University,5665 Peachtree Dunwoody Road
Atlanta, Georgia, 30342
Rocky Mountain Cancer Centers,1700 South Potomac Street
Aurora, Colorado, 80012
Texas Oncology-Austin,901 West 38th Street
Austin, Texas, 78705
Texas Oncology-Austin
Austin, Texas, 78731
Texas Oncology-Austin,4101 James Casey, Suite 100
Austin, Texas, 78745
University of Miami - Sylvester Comprehensive Cancer Center,2801 NE 213th St
Aventura, Florida, 33180
New York Cancer & Blood Specialists - Port Jeffers,72 East Main St.
Babylon, New York, 11702
Cancer Institute Ascension Saint Agnes
Baltimore, Maryland, 21229
Hematology Oncology Clinic - Baton Rouge
Baton Rouge, Louisiana, 70809
Summit Medical Group,1 Diamond Hill Road
Berkeley Heights, New Jersey, 07922
Magee-Womens Hospital of UPMC,200 Oxford Drive
Bethel Park, Pennsylvania, 15102
Northside Hospital,308 Deep South Farm Rd, Suite 200
Blairsville, Georgia, 30512
Florida Cancer Specialists,9776 Bonita Beach Road Southeast Suite 201 A
Bonita Springs, Florida, 34135
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215
Massachusetts General Hospital
Boston, Massachusetts, 02215
Rocky Mountain Cancer Centers
Boulder, Colorado, 80303
Florida Cancer Specialists,3630 Manatee Avenue West
Bradenton, Florida, 34205
Florida Cancer Specialists,5985 Silver Falls Run
Bradenton, Florida, 34211
SCRI - Florida Cancer Specialists - North Region R,403 S. Kings Ave.
Brandon, Florida, 33511
University of California Los Angeles - Jonsson Comprehensive Cancer Center,201 S. Buena Vista Street, Suite 200
Burbank, California, 91505
The Center for Cancer and Blood Disorders - Magnolia,11805 South Freeway
Burleson, Texas, 76028
Northside Hospital,228 Riverstone Dr.
Canton, Georgia, 30114
Florida Cancer Specialists,1030 Commerce Creek Blvd
Cape Coral, Florida, 33909
Virginia Oncology Associates,744 N. Battlefield Blvd
Chesapeake, Virginia, 23320
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Chicago, Illinois, 60611
University of Illinois Hospital and Health Sciences System (Outpatient Cancer Center)
Chicago, Illinois, 60612
Orchard Healthcare Research Inc,2845 North Sheridan Road, 1st Floor
Chicago, Illinois, 60657
SCRI - Florida Cancer Specialists - North Region R,3280 McMullen Booth Road
Clearwater, Florida, 33761
Rocky Mountain Cancer Centers,2312 N. Nevada Avenue
Colorado Springs, Colorado, 80907
Rocky Mountain Cancer Centers,6031 E. Woodman Rd.
Colorado Springs, Colorado, 80923
The Ohio State University Wexner Medical Center Clinical Laboratories
Columbus, Ohio, 43212
Zangmeister Cancer Center
Columbus, Ohio, 43219
University of Miami - Sylvester Comprehensive Cancer Center,5555 Ponce De Leon Blvd
Coral Gables, Florida, 33146
University of California Irvine Health Chao Family,1640 Newport Blvd
Costa Mesa, California, 92627
Magee-Womens Hospital of UPMC,3 St. Francis Way
Cranberry Township, Pennsylvania, 16066
Northside Hospital,1505 Northside Blvd, Suite 4600
Cumming, Georgia, 30041
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Dallas, Texas, 75246
Massachusetts General Hospital,102 Endicott Street
Danvers, Massachusetts, 01923
SCRI - Florida Cancer Specialists - West Palm Beach,224 Memorial Medical Parkway, Suite 300
Daytona Beach, Florida, 32117
University of Miami - Sylvester Comprehensive Cancer Center,1192 East Newport Center Drive
Deerfield Beach, Florida, 33442
Robert H. Lurie Comprehensive Cancer Center of Northwestern University,1 Kish Hospital Drive
DeKalb, Illinois, 60115
Robert H. Lurie Comprehensive Cancer Center of Northwestern University,10 Health Services Drive
DeKalb, Illinois, 60115
Texas Oncology-Denison
Denison, Texas, 75020
Rocky Mountain Cancer Centers,4700 E. Hale Parkway
Denver, Colorado, 80220
Tennessee Oncology, PLLC,103 Natchez Park Drive
Dickson, Tennessee, 37055
City of Hope
Duarte, California, 91010
Northside Hospital,3855 Pleasant Hill Rd., Suite 480
Duluth, Georgia, 30096
Regional Cancer Care Associates - East Brunswick
East Brunswick, New Jersey, 08816
Magee-Womens Hospital of UPMC,2500 West 12th Street
Erie, Pennsylvania, 16505
Magee-Womens Hospital of UPMC,201 State Street, 6 Main
Erie, Pennsylvania, 16550
Orchard Healthcare Research Inc,800 Austin Street, Suite 360, East Tower
Evanston, Illinois, 60202
Huntsman Cancer Institute, University of Utah,165 North University Avenue
Farmington, Utah, 84025
Summit Medical Group
Florham Park, New Jersey, 07932
Florida Cancer Specialists
Fort Myers, Florida, 33901
Florida Cancer Specialists,8981 Colonial Center Drive
Fort Myers, Florida, 33905
Florida Cancer Specialists,8260 Gladiolus Dr
Fort Myers, Florida, 33908
Regulatory Management Only: TRIO-US Central Administration
Fort Wayne, Indiana, 46845
The Center for Cancer and Blood Disorders - Magnolia
Fort Worth, Texas, 76104
Tennessee Oncology, PLLC,4488 Carothers Parkway
Franklin, Tennessee, 37067
SCRI - Florida Cancer Specialists - North Region R,6420 W. Newberry Road
Gainesville, Florida, 32605
Tennessee Oncology, PLLC,225 Big Station Camp Blvd
Gallatin, Tennessee, 37066
Robert H. Lurie Comprehensive Cancer Center of Northwestern University,300 Randall Road
Geneva, Illinois, 60134
Robert H. Lurie Comprehensive Cancer Center of Northwestern University,304 Randall Road
Geneva, Illinois, 60134
The West Clinic, PLLC dba West Cancer Center
Germantown, Tennessee, 38138
Nebraska Cancer Specialists,2730 W. Faidley Ave
Grand Island, Nebraska, 68803
Magee-Womens Hospital of UPMC,200 Village Drive
Greensburg, Pennsylvania, 15601
Ascension St. John Hospital
Grosse Pointe Woods, Michigan, 48236
John Theurer Cancer Center
Hackensack, New Jersey, 07601
Rutgers Cancer Institute of New Jersey,2575 Klockner Road
Hamilton, New Jersey, 08690
Comprehensive Cancer Centers of Nevada - Central V,10001 S. Eastern Avenue, Suite 108
Henderson, Nevada, 89052
Comprehensive Cancer Centers of Nevada - Central V,2460 W. Horizon Ridge Parkway
Henderson, Nevada, 89052
Comprehensive Cancer Centers of Nevada - Central V,1501 Wigwam Parkway, Suite 1300
Henderson, Nevada, 89074
Tennessee Oncology, PLLC,353 New Shackle Island Road
Hendersonville, Tennessee, 37075
Tennessee Oncology, PLLC,5653 First Blvd.
Hermitage, Tennessee, 37076
University of Miami - Sylvester Comprehensive Cancer Center,3850 Hollywood Blvd
Hollywood, Florida, 33021
Genesis Cancer and Blood Institute
Hot Springs, Arkansas, 71913
Genesis Cancer and Blood Institute,1456 Higdon Ferry Road Suite B.
Hot Springs, Arkansas, 71914
Oncology Consultants,1631 North Loop West
Houston, Texas, 77008
Oncology Consultants,925 Gessner
Houston, Texas, 77024
Oncology Consultants
Houston, Texas, 77030
University of Texas MD Anderson Cancer Center,1155 Pressler St
Houston, Texas, 77030
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030
Rutgers Cancer Institute of New Jersey,414 Grand Street
Jersey City, New Jersey, 07302
Saint Bernards Medical Center
Jonesboro, Arkansas, 72401
The University of Kansas Cancer Center,2000 Olathe Blvd
Kansas City, Kansas, 66160
The University of Kansas Cancer Center,2750 Clay Edwards Drive
Kansas City, Missouri, 64116
The University of Kansas Cancer Center,8700 North Green Hills Road
Kansas City, Missouri, 64154
University of California San Diego Moores Cancer
La Jolla, California, 92093
University of California Los Angeles - Jonsson Comprehensive Cancer Center,24302 Paseo de Valencia, Suite 200
Laguna Hills, California, 91505
Robert H. Lurie Comprehensive Cancer Center of Northwestern University,1000 N. Westmoreland Road
Lake Forest, Illinois, 60045
Rocky Mountain Cancer Centers,11750 West 2nd Place
Lakewood, Colorado, 80228
Rutgers Cancer Institute of New Jersey,600 River Avenue
Lakewood, New Jersey, 08701
SCRI - Florida Cancer Specialists - North Region R,100 Highland Avenue
Largo, Florida, 33770
Comprehensive Cancer Centers of Nevada - Central V,653 North Town Center Drive, Suite 402
Las Vegas, Nevada, 89144
Comprehensive Cancer Centers of Nevada - Central V,9280 W. Sunset Road Suite 100
Las Vegas, Nevada, 89148
Comprehensive Cancer Centers of Nevada - Central V,7445 Peak Drive
Las Vegas, Nevada, 89169
Comprehensive Cancer Centers of Nevada - Central V
Las Vegas, Nevada, 89169
Tennessee Oncology, PLLC,103 Physicians Way
Lebanon, Tennessee, 37090
SCRI - Florida Cancer Specialists - North Region R,521 North Lecanto Highway
Lecanto, Florida, 34461
The University of Kansas Cancer Center,4881 N.E. Goodview Circle
Lee's Summit, Missouri, 64064
Rocky Mountain Cancer Centers,22 West Dry Creek Circle
Littleton, Colorado, 80120
Rutgers Cancer Institute of New Jersey,94 Old Short Hills Road
Livingston, New Jersey, 07039
Rocky Mountain Cancer Centers,10107 Ridge Gate Parkway
Lone Tree, Colorado, 80124
Rutgers Cancer Institute of New Jersey,300 Second Ave
Long Branch, New Jersey, 07740
Rocky Mountain Cancer Centers,2030 Mountain View Ave Ste 210
Longmont, Colorado, 80124
Cancer and Blood Specialty Clinic
Los Alamitos, California, 90720
Norton Cancer Institute - Saint Matthews,234 E. Gray Strret
Louisville, Kentucky, 40202
Norton Cancer Institute - Saint Matthews,676 S. Floyd Street
Louisville, Kentucky, 40202
Norton Cancer Institute - Saint Matthews
Louisville, Kentucky, 40207
Norton Cancer Institute - Saint Matthews,4955 Norton Healthcare Blvd
Louisville, Kentucky, 40241
Northside Hospital,308 Coliseum Dr.
Macon, Georgia, 31217
Virginia Cancer Institute,7501 Right Flank Road
Mechanicsville, Virginia, 23116
University of Miami - Sylvester Comprehensive Cancer Center,1400 NW 12th Ave
Miami, Florida, 33136
University of Miami - Sylvester Comprehensive Cancer Center
Miami, Florida, 33136
University of Miami - Sylvester Comprehensive Cancer Center,8932 S.W. 97 Ave
Miami, Florida, 33176
Perlmutter Cancer Center - Manhattan - 34th Street,259 First Street
Mineola, New York, 11501
Regional Cancer Care Associates - East Brunswick,9 Centre Drive
Monroe, New Jersey, 08831
Magee-Womens Hospital of UPMC,400 Oxford Drive
Monroeville, Pennsylvania, 15146
Tennessee Oncology, PLLC,1840 Medical Center Parkway
Murfreesboro, Tennessee, 37129
Florida Cancer Specialists,1100 Goodlette Road
Naples, Florida, 34102
Tennessee Oncology, PLLC,2004 Hayes Street
Nashville, Tennessee, 37203
Tennessee Oncology, PLLC,SCRI Oncology Partners
Nashville, Tennessee, 37203
Tennessee Oncology, PLLC
Nashville, Tennessee, 37203
Tennessee Oncology, PLLC,4220 Harding Rd
Nashville, Tennessee, 37205
Tennessee Oncology, PLLC,3443 Dickerson Road
Nashville, Tennessee, 37207
Tennessee Oncology, PLLC,397 Wallace Road
Nashville, Tennessee, 37211
Regional Cancer Care Associates - East Brunswick,34-36 Progress Street
New Brunswick, New Jersey, 08820
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08901
New York Cancer & Blood Specialists - Port Jeffers,1 Delaware Dr.
New Hyde Park, New York, 11042
Perlmutter Cancer Center - Manhattan - 34th Street
New York, New York, 10016
NYP/Columbia Univeresity Medical Center/Herbert Irving Comprehensive Cancer Center
New York, New York, 10032
Rutgers Cancer Institute of New Jersey,150 Bergen St.
Newark, New Jersey, 07103
Rutgers Cancer Institute of New Jersey,201 Lyons Avenue
Newark, New Jersey, 07112
Piedmont Cancer Institute - Atlanta,775 Poplar Road
Newnan, Georgia, 30265
City of Hope,1601 Avocado Ave
Newport, California, 92660
Virginia Oncology Associates,1051 Loftis Blvd Suite 100
Newport News, Virginia, 23606
Massachusetts General Hospital,2014 Washington St
Newton, Massachusetts, 02462
Virginia Oncology Associates
Norfolk, Virginia, 23502
Eastern Connecticut Hematology and Oncology Associates
Norwich, Connecticut, 06360
SCRI - Florida Cancer Specialists - North Region R,4945 SW 49th Place
Ocala, Florida, 34474
Nebraska Cancer Specialists,8303 Dodge Street
Omaha, Nebraska, 68114
Nebraska Cancer Specialists
Omaha, Nebraska, 68130
University of California Irvine Health Chao Family
Orange, California, 92868
SCRI - Florida Cancer Specialists - North Region R,2824 Enterprise Rd
Orange City, Florida, 32763
Advent Health Medical Group,2501 North Orange Ave
Orlando, Florida, 32804
SCRI - Florida Cancer Specialists - North Region R,70 W. Gore Street
Orlando, Florida, 32806
The University of Kansas Cancer Center,12200 W. 110th Street
Overland Park, Kansas, 66210
The University of Kansas Cancer Center,10710 Nall Avenue
Overland Park, Kansas, 66211
The University of Kansas Cancer Center,10730 Nall Avenue
Overland Park, Kansas, 66211
Nebraska Cancer Specialists,611 Fenwick Dr
Papillion, Nebraska, 68046
Saint Bernards Medical Center,4000 Linwood Drive
Paragould, Arkansas, 72450
City of Hope,209 Fair Oaks Ave
Pasadena, California, 91030
New York Cancer & Blood Specialists - Port Jeffers,365 East Main St.
Patchogue, New York, 11772
Virginia Cancer Institute,210 Medical Park Boulevard
Petersburg, Virginia, 23805
University of Pennsylvania Abramson Cancer Center
Philadelphia, Pennsylvania, 19104
Magee-Womens Hospital of UPMC,300 Halket Street
Pittsburgh, Pennsylvania, 15213
Magee-Womens Hospital of UPMC
Pittsburgh, Pennsylvania, 15213
Magee-Womens Hospital of UPMC,5115 Centre Avenue
Pittsburgh, Pennsylvania, 15232
Magee-Womens Hospital of UPMC,9100 Babcock Boulevard
Pittsburgh, Pennsylvania, 15237
University of Miami - Sylvester Comprehensive Cancer Center,8100 SW 10 Street
Plantation, Florida, 33324
Florida Cancer Specialists,22395 Edgewater Drive
Port Charlotte, Florida, 33980
New York Cancer & Blood Specialists - Port Jeffers,1500 Rte, 112, Building 4
Port Jefferson, New York, 11776
New York Cancer & Blood Specialists - Port Jeffers,49 Rte. 347, Newconset Hwy
Port Jefferson Station, New York, 11776
New York Cancer & Blood Specialists - Port Jeffers
Port Jefferson Station, New York, 11776
Northwest Cancer Specialists, PC,5050 NE Hoyt St.
Portland, Oregon, 97213
Northwest Cancer Specialists, PC,265 N. Broadway
Portland, Oregon, 97227
Rhode Island Hospital
Providence, Rhode Island, 02903
Rhode Island Hospital,164 Summit Ave, Fain 275A
Providence, Rhode Island, 02906
Rocky Mountain Cancer Centers,3676 Parker Blvd
Pueblo, Colorado, 81008
Rocky Mountain Cancer Centers,525 W. 15th Street
Pueblo, Colorado, 81008
Virginia Cancer Institute,1401 Johnston-Willis Drive
Richmond, Virginia, 23235
Virginia Cancer Institute
Richmond, Virginia, 23298
New York Cancer & Blood Specialists - Port Jeffers,750 Old County Rd. Suite 4
Riverhead, New York, 11901
Mayo Clinic
Rochester, Minnesota, 55905
Huntsman Cancer Institute, University of Utah,1280 E. Stringham Avenue
Salt Lake City, Utah, 84106
Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah, 84112
Mays Cancer Center
San Antonio, Texas, 78229
University of California Los Angeles - Jonsson Comprehensive Cancer Center,892 Aerovista Place, Suite 240
San Luis Obispo, California, 93401
Sansum Clinic
Santa Barbara, California, 93105
University of California Los Angeles - Jonsson Comprehensive Cancer Center,2020 Santa Monica Blvd, Suite 600
Santa Monica, California, 90404
University of California Los Angeles - Jonsson Comprehensive Cancer Center,2336 Santa Monica, Suites 302 and 304
Santa Monica, California, 90404
University of California Los Angeles - Jonsson Comprehensive Cancer Center
Santa Monica, California, 90404
St. Jude Hospital Yorba dba St. Joseph Heritage Healthcare
Santa Rosa, California, 95403
Florida Cancer Specialists,600 North Cattlemen Road
Sarasota, Florida, 34232
Florida Cancer Specialists,1970 Golf Street
Sarasota, Florida, 34236
Magee-Womens Hospital of UPMC,100 Fairfield Dr
Seneca, Pennsylvania, 16346
Tennessee Oncology, PLLC,120 Frank Martin Road
Shelbyville, Tennessee, 37160
Orchard Healthcare Research Inc
Skokie, Illinois, 60077
Tennessee Oncology, PLLC,300 Stonecrest Blvd
Smyrna, Tennessee, 37167
Sansum Clinic,2040 Viborg Road
Solvang, California, 93463
Regional Cancer Care Associates - East Brunswick,75 Veronica Avenue
Somerset, New Jersey, 08873
Rutgers Cancer Institute of New Jersey,110 Rehill Ave
Somerville, New Jersey, 08876
Huntsman Cancer Institute, University of Utah,5126 West Daybreak Parkway
South Jordan, Utah, 84009
The West Clinic, PLLC dba West Cancer Center,7668 Airways Blvd
Southaven, Mississippi, 38671
Ascension Providence Hospital Southfield Cancer Center
Southfield, Michigan, 48075
SCRI - Florida Cancer Specialists - North Region R,7154 Medical Center Drive
Spring Hill, Florida, 34608
SCRI - Florida Cancer Specialists - North Region R,1201 Fifth Avenue North
St. Petersburg, Florida, 33705
SCRI - Florida Cancer Specialists - North Region R
St. Petersburg, Florida, 33705
Piedmont Cancer Institute - Atlanta,1240 Eagles Landing Pkwy
Stockbridge, Georgia, 30281
SCRI - Florida Cancer Specialists - West Palm Beach,301 SE Ocean Blvd, Suite 102
Stuart, Florida, 34994
SCRI - Florida Cancer Specialists - North Region R,3402 West Dr. Martin Luther King Jr. Boulevard
Tampa, Florida, 33607
SCRI - Florida Cancer Specialists - North Region R,4100 Waterman Way
Tavares, Florida, 32778
New York Cancer & Blood Specialists - Port Jeffers,12 East 86th St, Suite 4
The Bronx, New York, 10028
Montefiore Medical Center - Montefiore Medical Park
The Bronx, New York, 10467
New York Cancer & Blood Specialists - Port Jeffers,2330 Eastchester Road, Suite 360
The Bronx, New York, 10469
SCRI - Florida Cancer Specialists - North Region R,1400 US Highway 441 N
The Villages, Florida, 32159
Rocky Mountain Cancer Centers,8820 Huron Street
Thornton, Colorado, 80260
Northwest Cancer Specialists, PC
Tigard, Oregon, 97223
Rutgers Cancer Institute of New Jersey,99 Highway 37 West
Toms River, New Jersey, 08755
City of Hope,5215 Torrance Blvd
Torrance, California, 90503
Torrance Memorial Physician Network - Cancer Care
Torrance, California, 90505
SCRI - Florida Cancer Specialists - North Region R,9320 State Road 54
Trinity, Florida, 34655
Arizona Oncology Associates, PC-Hope,1845 W Orange Grove Rd
Tucson, Arizona, 85704
Arizona Oncology Associates, PC-Hope,2070 W. Rudasill Rd.
Tucson, Arizona, 85704
Arizona Oncology Associates, PC-Hope
Tucson, Arizona, 85711
Arizona Oncology Associates, PC-Hope,1620 West St. Mary's Road
Tucson, Arizona, 85745
City of Hope,1100 San Bernardino Rd
Upland, California, 91786
Northwest Cancer Specialists, PC,210 SE 136th Avenue
Vancouver, Washington, 98684
Florida Cancer Specialists,836 Sunset Lake Blvd
Venice, Florida, 34292
SCRI - Florida Cancer Specialists - West Palm Beach,3730 7th Terrace, Suite 101
Vero Beach, Florida, 32960
Virginia Oncology Associates,1950 Glenn Mitchell Drive
Virginia Beach, Virginia, 23456
Robert H. Lurie Comprehensive Cancer Center of Northwestern University,4405 Weaver Parkway
Warrenville, Illinois, 25731
Robert H. Lurie Comprehensive Cancer Center of Northwestern University,4455 Weaver Parkway
Warrenville, Illinois, 60555
Magee-Womens Hospital of UPMC,470 Johnson Road
Washington, Pennsylvania, 15301
The Center for Cancer and Blood Disorders - Magnolia,920 Santa Fe Drive
Weatherford, Texas, 76086
SCRI - Florida Cancer Specialists - West Palm Beach,1037 S. State Road 7, Bldg B, Suite 303
Wellington, Florida, 33414
Rutgers Cancer Institute of New Jersey,100 State Route 36
West Long Branch, New Jersey, 07764
SCRI - Florida Cancer Specialists - West Palm Beach
West Palm Beach, Florida, 33401
University of California Los Angeles - Jonsson Comprehensive Cancer Center,1250 La Venta Dr, Suite 100
Westlake Village, California, 91361
The University of Kansas Cancer Center
Westwood, Kansas, 66205
Robert H. Lurie Comprehensive Cancer Center of Northwestern University,25 N Winfield Road
Winfield, Illinois, 60190
SCRI - Florida Cancer Specialists - North Region R,460 N Orlando Ave
Winter Park, Florida, 32789
Magee-Womens Hospital of UPMC,1703 Innovation Drive
York, Pennsylvania, 17408
Hematology Oncology Clinic - Baton Rouge,1673 E Mount Please Drive
Zachary, Louisiana, 70791
Japan28 sites
Aichi Cancer Center Hospital
Aichi, 464-8681
Tohoku University Hospital
Aoba-ku, 980-8574
Juntendo University Hospital
Bunkyō City, 113-8431
Chiba Cancer Center
Chūōku, 260-8717
Osaka Prefectural Hospital Organization Osaka International Cancer Institute
Chūōku, 541-8567
NHO Shikoku Cancer Center
Ehime, 791-0280
Fukushima Medical University Hospital
Fukushima
Saitama Cancer Center
Inamachi, 362-0806
Hakuaikai Sagara Hospital
Kagoshima, 892-0833
Tokai University Hospital
Kanagawa, 259-1193
National Cancer Center Hospital East
Kashiwa, 277-8577
The Cancer Institute Hospital of JFCR
Kōtoku, 135-8550
Kumamoto University Hospital
Kumamoto, 860-8556
Kure Medical Center And Chugoku Cancer Center
Kure, 737-0023
Mie University Hospital
Mie, 514-8507
Nagoya University Hospital
Nagoya, 466-8560
Nagoya City University Hospital
Nagoya, 467-8602
Hiroshima City Hiroshima Citizens Hospital
Nakaku, 730-8518
NIigata Cancer Center Hospital
Niigata, 951-8566
Okayama University Hospital
Okayama, 700-8558
Gunma Prefectural Cancer Center
Ōta-ku, 373-8550
Kyoto University Hospital
Sakyo-ku, 606-8507
Hokkaido Cancer Center
Sapporo, 003-0804
Shizuoka Cancer Center
Shizuoka, 411-8777
Shizuoka General Hospital
Shizuoka, 420-8527
Osaka University Hospital
Suita, 565-0871
Showa University Hospital
Tokyo, 142-8555
Kanagawa Cancer Center
Yokohama, 241-8515
Italy19 sites
IRCCS Istituto Tumori "Giovanni Paolo II"
Bari, 70124
SSD Oncologia Medica Addarii-Zamagni, IRCSS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant'Orsola
Bologna
UO Oncologia, ASST degli Spedali Civili di Brescia
Brescia, 25123
IRCCS Ospedale Policlinico San Martino
Genova GE, 16132
S.C. Oncologia medica, ASST di Lecco
Lecco, 23900
Presidio Ospedaliero di Lucca
Lucca, 55100
Istituto Europeo di Oncologia
Milan, 20141
Ospedale San Raffaele
Milan, 20132
Fondazione IRCCS - Istituto Nazionale dei Tumori
Milan, 20133
Centro Ricerca Fase I, Fondazione IRCSS San Gerado dei Tintori
Monza, 20090
AOU "Luigi Vanvitelli"
Naples, 80131
Oncologia Medica Senologica Sperimentale - Istituto Nazionale Tumori IRCCS Fondazione G. Pascale
Naples, 80131
AOU Maggiore della Carita
Novara, 28100
Istituto Oncologico Veneto - IRCCS
Padova, 35128
S.O.C Oncologia Medica, Nuovo Ospedale di Prato Santo Stefano
Prato, 59100
Ospedale Generale Provinciale - Macerata
Province of Macerata, 62100
Policlinico di Roma
Roma, 00161
Fondazione Policlinico Universitario Agostino Geme
Rome, 00168
Azienda Ospedaliera Universitaria Senese - Losped
Siena, 53100
Germany18 sites
Helios Klinikum Berlin-Buch
Berlin, 13125
: Gynakologisches Zentrum Bonn, Schwerpunkt Gyn. Onkologie,
Bonn, 53111
Marienhospital Bottrop
Bottrop, 46236
Klinik Frauenheilkunde, Uniklinik ClO, Studienzentrale
Cologne, 50937
Universitätsklinikum Erlangen, Frauen klinik
Erlangen, 91054
Kliniken Essen-Mitte - Evangelische Huyssens-Stift
Essen, 45136
Praxis für interdisziplinäre Onkologie & Hämatolog
Freiburg im Breisgau, 79110
: Universitätsklinikum Hamburg-Eppendorf
Hamburg, 20246
Facharztzentrum Eppendorf
Hamburg, 20249
Nationales Centrum für Tumorerkrankungen
Heidelberg, 69120
Universitätsklinikum Schleswig-Holstein Institut fur Klinische Chermie
Lübeck, 23538
Universitatsklinikum Mannheim GmBH, Frauenklinik
Mannheim, 68167
EV. Krankenhaus Bethesda - Johanniter GmbH, Station 1 Brustzentrum Niederrhein
Mönchengladbach, 41061
Rotkreuzklinikum Munchen Frauenklinik
München, 80637
Klinik und Poliklinik für Frauenheilkunde
München, 81675
Universitätsklinikum Münster, Bereich Senologie an der klinik fur Frauenheilkunde und Gerburtschilfe
Münster, 48149
Universitatsklinikum Tubingen
Tübingen, 72076
St. Josefs-Hospital Wiesbaden GmbH, Gynakologie und Geburtshilfe
Wiesbaden, 65189
Spain17 sites
Hospital Teresa Herrera - Materno Infantil
A Coruña, 15006
Hospital Universitari Dexeus
Barcelona, 08028
Hospital Clinic Barcelona
Barcelona, 08036
Hospital Clínic de Barcelona
Barcelona, 08036
Hospital de la Santa Creu i Sant Pau
Barcelona, 8023
Hospital Universitari Vall d'Hebrón
Barcelona, 8035
Hospital Universitario de Basurto
Bilbao, 48013
Hospital Universitari Arnau de Vilanova
Lleida, 25198
Hospital General Universitario Gregorio Marañón
Madrid, 28007
MD Anderson Cancer Centre Madrid
Madrid, 28033
Hospital Universitario Fundación Jiménez Díaz
Madrid, 28040
Hospital Universitario Virgen de la Victoria
Málaga, 29010
Hospital General Universitario Morales Meseguer
Murcia, 30008
Hospital Universitario de Canarias
Santa Cruz de Tenerife, 38320
Hospital Unviersitario Virgen del Rocio
Seville, 41013
Hospital Universitario Virgen Macarena
Seville, 41071
Hospital Clínico Universitario de Valencia
Valencia, 46010
France16 sites
Sainte Catherine Institut du Cancer Avignon Provence
Avignon, 84918
Centre Hospitalier Régional et Universitaire de Be
Besançon, 25030
Polyclinique Bordeaux Nord Aquitaine
Bordeaux, 33000
Hôpital Morvan, Institut de cancérologie
Brest, 29200
Centre de Lutte contre le Cancer - François Bacles
Caen, 14000
Centre Jean Perrin
Clermont-Ferrand, 63011
Centre Leon Berard
Lyon, 69373
Institut Paoli-Calmettes
Marseille, 13273
Centre de Cancérologie du Grand Montpellier
Montpellier, 34070
Institut Régional du Cancer de Montpellier
Montpellier, 34298
Hôpital Privé du Confluent
Nantes, 44202
Hospices Civils de Lyon, Hôpital Lyon Sud
Pierre-Bénite, 69495
Centre Armoricain de Radiothérapie, dImagerie Méd
Plérin, 22190
Centre Eugène Marquis
Rennes, 35042
Institut Claudius Regaud - IUCT-O
Toulouse
Institut Gustave Roussy
Villejuif, 94800
Brazil14 sites
Hospital Araújo Jorge - Associacao de Combate ao Cancer em Goias - ACCG
Goiânia, 74605-070
Centro de Pesquisa Clinica Em Oncologia - ONCOSITE
Ijuí, 98700-000
Hospital de Clinicas de Porto Alegre - HCPA
Itajaí, 88301-220
Centro de Pesquisas Clinicas da Fundacao Doutor Amaral Carvalho - Hospital Amarval Carvalho
Jaú, 17210080
Associacao Hosptialar Moinos de Vento - Hospital Moinhos de Vento
Porto Alegre, 90035-00
Hospital de Clínicas de Porto Alegre
Porto Alegre, 90035-903
Hospital Sao Lucas da PUCRS
Porto Alegre, 90610001
Instituto Nacional de Câncer - Brazil
Rio de Janeiro
Núcleo de Oncologia da Bahia
Salvador, 40170170
CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia - Centro Universitário FMABC
Santo André, 09060-650
Real e Benemerita Associacao Portuguesa de Beneficencia - Hospital Beneficencia Portuguesa (BP) - Unidade Paulista
São Paulo, 01323-001
Clinica de Pesquisas e Centro de Estudos em Oncolo
São Paulo, 1317000
Fundação Pio XII - Hospital de Câncer de Barretos
São Paulo, 14784400
Nucleo de Pesquisa Clinica da Rede Sao Camilo
São Paulo, 4014002
Australia12 sites
Cancer Research SA (CRSA)
Adelaide, South Australia, 5000
Border Medical Oncology
Albury, New South Wales, 2640
Monash Medical Centre
Clayton, Victoria, 3168
Icon Cancer Centre Hobart
Hobart, Tasmania, 7000
Saint George Hospital - Australia
Kogarah, New South Wales, 2217
Austin Hospital
Melbourne, Victoria, 3084
Breast Cancer Research Center - Western Australia
Nedlands, Western Australia, 6009
Mater Hospital - North Sydney
North Sydney, New South Wales, 2060
Peter MacCallum Cancer Centre
Parkville, Victoria, 3050
Mater Misericordiae Limited and Mater Research Limited
South Brisbane, Queensland, 4101
GenesisCare - North Shore
St Leonards, New South Wales, 2065
Princess Alexandra Hospital
Woolloongabba, Queensland, 4102
Canada12 sites
Tom Baker Cancer Centre
Calgary, T2N 5G2
Cross Cancer Institute
Edmonton, T6G 1Z2
QEII Health Sciences Centre
Halifax, B3H 1V7
Grand River Regional Cancer Centre at Grand River Hospital
Kitchener, N2G 1G3
London Health Sciences Centre
London, N6A 5W9
Jewish General Hospital
Montreal, H3T 1E2
McGill University Health Centre
Montreal, H4A 3J1
Princess Margaret Cancer Centre - University Health Network
Ontario, M5G 2M9
Ottawa Hospital - General Campus
Ottawa, K1H 8L6
Sunnybrook Research Institute
Toronto, M4N 3M5
Mount Sinai Hospital
Toronto, M5G 1X5
British Columbia Cancer - Vancouver
Vancouver, V5Z 4E6
Turkey (Türkiye)12 sites
Baskent Uni. Dr Turgut Noyan Uyg. ve Aras. Merkezi
Adana, 1120
Ankara Il Saglik Mudurlugu SBU Gulhane Egitim Ve A
Ankara, 6010
Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
Ankara, 6200
Memorial Ankara Hastanesi
Ankara, 6520
Hacettepe Üniversitesi Hastanesi
Ankara
Trakya Universitesi Tip Fakultesi Hastanesi
Edirne, 22030
Istanbul Il Saglik Mudurlugu Goztepe Prof. Dr. Sul
Istanbul, 34000
Medipol Mega Universite Hastanesi
Istanbul, 34214
Ege Universitesi Hastanesi
Izmir, 35100
Medicana International Izmir Hastanesi
Izmir, 35575
Acibadem Maslak Hastanesi
Sariyer
VKV Amerikan Hastanesi
Şişli, 34365
Mexico10 sites
Icaro Investigaciones en Medicina S.A. de C.V.
Chihuahua City, 31000
Centro para el Desarrollo de la Medicina
Culiacán, 80230
Panamerican Clinical Research Mexico - Guadalajara
Guadalajara, 44670
Medical Care and Research S.A. de C.V
Mérida, 97070
Fucam A.C.
México, 4980
Cryptex Investigación Clínica
Mexico City, 06100
Avix Investigacion Clinica S.C.
Monterrey, 64710
Oncológico Potosino
San Luis Potosí City, 78209
FAICIC Clínical Research
Veracruz, 91900
iBiomed - Investigacion Biomedica para el Desarrol
Zapopan, 45070
Israel9 sites
Soroka Medical Center
Beersheba, 8410101
Rambam Health Care Campus
Haifa, 3109601
Shaare Zedek Medical Center
Jerusalem, 9103102
Hadassah - Hebrew University Medical Center
Jerusalem
Meir Medical Center
Kfar Saba, 4428164
Rabin Medical Center
Petah Tikva, 4941492
Kaplan Medical Center
Rehovot, 7661041
Sheba Medical Center Hospital - Tel Hashomer
Tel Aviv, 52621
Tel Aviv Sourasky Medical Center
Tel Aviv, 64239
Belgium8 sites
Institut Jules Bordet
Anderlecht, 1070
Algemeen Ziekenhuis Klina
Brasschaat, 2930
Cliniques Universitaires Saint-Luc
Brussels, 1200
Universitair Ziekenhuis Brussel
Brussels
Grand Hopital de Charleroi - Notre Dame
Charleroi, 6000
Universitair Ziekenhuis Gent
Ghent, 9000
UZ Leuven
Leuven, 3000
Centre Hospitalier Universitaire Université Cathol
Namur, 5000
Malaysia8 sites
Hospital Pulau Pinang
George Town, 10450
Hospital Sultan Ismail
Johor Bahru, 81100
Hospital Kuala Lumpur
Kuala Lumpur, 47500
Pantai Hospital Kuala Lumpur
Kuala Lumpur, 59100
University Malaya Medical Centre (UMMC)
Kuala Lumpur, 59100
Institut Kanser Negara
Putrajaya, 62250
Hospital Wanita dan Kanak-Kanak Sabah
Sabak Bernam, 88996
Sarawak General Hospital
Sarawak, 93586
South Korea8 sites
National Cancer Center - Korea
Goyang-si Gyeonggi-do, 10408
Seoul National University Bundang Hospital
Seongnam-si, 13620
Severance Hospital
Seoul, 03722
Asan Medical Center
Seoul, 05505
Samsung Medical Center
Seoul, 06351
Korea University Anam Hospital
Seoul, 2841
Seoul National University Hospital
Seoul, 3080
The Catholic University of Korea, Seoul St. Mary's Hospital
Seoul, 6591
Taiwan8 sites
Changhua Christian Hospital
Changhua, 50006
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, 807
Taipei Medical University-Shuang Ho Hospital
New Taipei City, 235
National Cheng Kung University Hospital
Tainan, 704
Chi Mei Hospital, Liouying
Tainan, 73657
National Taiwan University Hospital
Taipei, 100
Taipei Veterans General Hospital
Taipei, 11217
Linkou Chang Gung Memorial Hospital
Taoyuan, 333
United Kingdom8 sites
NHS Lothian
Edinburgh, EH4 2XU
Clinical Trials Unit Lvl 0 Cancer Research UK Beatson Institute
Glasgow, G12 0YN
Leeds Teaching Hospitals NHS Trust
Leeds, LS9 7TF
: Barts Health NHS Trust, St Hospital
London, EC1M 6BQ
Royal Free London NHS Foundation Trust
London, NW2 2QG
Guy's and Saint Thomas' NHS Foundation Trust
London, SE1 9RT
University College London Hospitals
London, WC1E 6BT
Nottingham University Hospitals NHS Trust
Nottingham, NG5 1PB
Poland7 sites
Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii
Gdansk, 80-952
Narodowy Instytut Onkologii im. Marii Sklodowskiej
Gliwice, 44-102
SP ZOZ Opolskie Centrum Onkologii im. prof. Tadeusza Koszarowskiego
Opole, 45-061
Wielkopolskie Centrum Onkologii im. Marii Sklodowskiej-Curie
Poznan, 61- 866
Mazowiecki Szpital Wojewódzki im. w. Jana Pawa II w
Siedlce, 08-110
Narodowy Instytut Onkologii im.Marii Marii Sklodowskiejs
Warsaw, 02-781
Wojskowy Instytut Medyczny
Warsaw, 04-141
Argentina6 sites
Hospital Británico de Buenos Aires
Buenos Aires, 1426
Instituto de Oncología Ángel H. Roffo
CABA, 1417
Fundacion CORI para la Investigacioy y Prevención del Cancer
Capital, F5300COE
Instituto de Oncologia de Rosario
Rosario, 2000
CAIPO Centro Para La Atención Integral Del Pacient
San Miguel de Tucumán, 4000
Clinica Viedma
Viedma, 8500
Czechia6 sites
Masarykuv Onkologicky Ustav, Klinika Komplexni Onkologicke Pece
Brno, 65653
Fakultní Nemocnice Hradec Králové
Hradec Králové, 500 05
Fakultní Thomayerova nemocnice
Hradec Králové, 50005
Fakultni nemocnice Olomouc, Onkologicka klinika
Olomouc, 77520
Fakultní Nemocnice Královské Vinohrady, Radioterapeuticka a onkologicka klinika
Prague, 100 34
Vseobecna Fakultni Nemocnice v Praze, Onkologicka klinika
Prague, 12808
Austria5 sites
Medizinische Universität Innsbruck
Innsbruck, 06020
Ordensklinikum Linz GmbH Barmherzige Schwestern
Linz, 4010
Landeskrankenhaus Salzburg
Salzburg, A-5020
Universitätsklinikum Sankt Pölten
Sankt Pölten, 3100
Medizinische Universität Wien
Vienna, 1090
Chile5 sites
Oncovida - Santiago
Providencia, 7510035
Clínica Alemana
Santiago, 7630000
Clínica IRAM
Santiago
Centro de Cancer Pontificia Universidad Catolica
Santiago Region, 8330032
James Lind Centro de Investigacion del Cancer
Temuco
Switzerland5 sites
Kantonsspital Baden
Baden, 5404
Kantonsspital Baselland - Standort Liestal
Liestal, 4410
Kantonsspital Sankt Gallen
Sankt Gallen, 9007
Kantonsspital Winterthur
Winterthur, 8401
Brust-Zentrum Zurich
Zurich, 8008
Hong Kong4 sites
Department of Medicine, Queen Mary Hospital
Hong Kong, 999077
Hong Kong Sanatorium and Hospital
Hong Kong
Tuen Mun Hospital
Hong Kong
Prince of Wales Hospital - Hong Kong
New Territories, 999077
Hungary4 sites
Orszagos Onkologiai Intezet
Budapest, 1122
Uzsoki Utcai Kórház
Budapest, 1145
Debreceni Egyetem Klinikai Központ
Debrecen, 4032
Petz Aladár Egyetemi Oktató Kórház - Gy?r
Győr, 9024
Netherlands4 sites
Amphia Ziekenhuis - Breda Langendijk
Breda, 4818 CK
Universitair Medisch Centrum Groningen
Groningen, 9700 RB
Medisch Centrum Leeuwarden
Leeuwarden, 8934 AD
Erasmus Medisch Centrum
Rotterdam
South Africa3 sites
Hopelands Cancer Centre
Hilton, 3245
The Medical Oncology Centre of Rosebank
Johannesburg, 2196
University of Pretoria
Pretoria, 0002
About this study
Official title: A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's choice (TPC) and pembrolizumab in participants with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors express programmed cell death ligand 1 (PD-L1).
- Conditions
- Triple Negative Breast Cancer, PD-L1 Positive
- Being tested
- Sacituzumab Govitecan-hziy, Pembrolizumab, Paclitaxel, nab-Paclitaxel, Gemcitabine
- Medical subject headings
- Triple Negative Breast Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Sacituzumab Govitecan-hziyDrug
Also called IMMU-132, Trodelvy™, GS-0132
Administered intravenously
PembrolizumabDrug
Also called KEYTRUDA®
Administered intravenously
PaclitaxelDrug
Also called Taxol®
Administered intravenously
nab-PaclitaxelDrug
Also called Abraxane®
Administered intravenously
GemcitabineDrug
Also called Gemzar
Administered intravenously
CarboplatinDrug
Administered intravenously
| Study group | Role | What they receive |
|---|---|---|
| Sacituzumab Govitecan-hziy (SG) + Pembrolizumab | Experimental | Participants will receive SG 10 mg/kg on Days 1 and 8 of 21-day cycles and pembrolizumab 200 mg on Day 1 of 21-day cycles
Pembrolizumab will be administered for a maximum of 35 cycles. Receives: Drug: Sacituzumab Govitecan-hziy; Drug: Pembrolizumab |
| Pembrolizumab + Treatment of Physician's Choice (TPC) | Active comparator | Participants will receive pembrolizumab 200 mg on Day 1 of each 21-day cycle (maximum 35 cycles) plus TPC determined prior to randomization from 1 of the 3 allowed regimens:
* Paclitaxel 90 mg/m^2 on Days 1, 8, and 15 of 28-day cycles
* nab-Paclitaxel 100 mg/m^2 on Days 1, 8, and 15 of 28-day cycles
* Gemcitabine 1000 mg/m^2 + carboplatin area under the curve (AUC) 2 on Days 1 and 8 of 21-day cycles Receives: Drug: Pembrolizumab; Drug: Paclitaxel; Drug: nab-Paclitaxel; Drug: Gemcitabine; Drug: Carboplatin |
What is being measured
The primary outcome is the main question the study is designed to answer.
Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
PFS is defined as the time from the date of randomization until the date of objective progressive disease (PD) or death (whichever comes first).
Measured: Randomization up to approximately 33 months
Secondary outcomes (11)
Overall Survival (OS)
OS is defined as the time from the date of randomization until death due to any cause.
Measured: Randomization up to approximately 53 months
Objective Response Rate (ORR) as Assessed by BICR per RECIST Version 1.1
ORR is defined as the proportion of participants who achieve complete response (CR) or partial response (PR) that is confirmed at least 4 weeks after initial documentation of response.
Measured: Randomization up to approximately 53 months
Duration of Response (DOR) as Assessed by BICR per RECIST Version 1.1
DOR is defined as the time from the first documentation of CR or PR to the earlier of the first documentation of objective PD or death from any cause (whichever comes first).
Measured: Randomization up to approximately 53 months
Time to Response (TTR) as Assessed by BICR per RECIST Version 1.1
TTR is defined as the time from the date of randomization until the first documentation of CR or PR.
Measured: Randomization up to approximately 53 months
Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)
Measured: First dose date up to 53 months plus 30 days
Percentage of Participants Experiencing Clinical Laboratory Abnormalities
Measured: First dose date up to 53 months plus 30 days
Time to Deterioration (TTD) in Global Health Status/Quality of Life (QoL) Scale as Measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, Core Questionnaire, Version 3.0 (EORTC QLQ-C30)
The EORTC QLQ-C30 is a questionnaire to assess quality of life of cancer patients, it is composed of 30 questions (items) resulting in 5 functional scales, 1 global health status scale, 3 symptom scales, and 6 single items. Scoring of the QLQ-C30 is performed according to QLQ-C30 Scoring manual. All of the scales and single-item measures range in score from 0 to 100. Higher score for the functioning scales and global health status denote a better level of functioning (i.e. a better state of the participant), while higher scores on the symptom and single-item scales indicate a higher level of symptoms (i.e. a worse state of the participant).
Measured: Randomization up to approximately 53 months
TTD of Pain Score as Measured by EORTC QLQ-C30
The EORTC QLQ-C30 is a questionnaire to assess quality of life of cancer patients, it is composed of 30 questions (items) resulting in 5 functional scales, 1 global health status scale, 3 symptom scales, and 6 single items. Scoring of the QLQ-C30 is performed according to QLQ-C30 Scoring manual. All of the scales and single-item measures range in score from 0 to 100. Higher score for the functioning scales and global health status denote a better level of functioning (i.e. a better state of the participant), while higher scores on the symptom and single-item scales indicate a higher level of symptoms (i.e. a worse state of the participant).
Measured: Randomization up to approximately 53 months
TTD of Fatigue Score as Measured by EORTC QLQ-C30
The EORTC QLQ-C30 is a questionnaire to assess quality of life of cancer patients, it is composed of 30 questions (items) resulting in 5 functional scales, 1 global health status scale, 3 symptom scales, and 6 single items. Scoring of the QLQ-C30 is performed according to QLQ-C30 Scoring manual. All of the scales and single-item measures range in score from 0 to 100. Higher score for the functioning scales and global health status denote a better level of functioning (ie, a better state of the participant), while higher scores on the symptom and single-item scales indicate a higher level of symptoms (ie, a worse state of the participant).
Measured: Randomization up to approximately 53 months
TTD of Physical Functioning Domain Score as Measured by EORTC QLQ-C30
The EORTC QLQ-C30 is a questionnaire to assess quality of life of cancer patients, it is composed of 30 questions (items) resulting in 5 functional scales, 1 global health status scale, 3 symptom scales, and 6 single items. Scoring of the QLQ-C30 is performed according to QLQ-C30 Scoring manual. All of the scales and single-item measures range in score from 0 to 100. Higher score for the functioning scales and global health status denote a better level of functioning (ie, a better state of the participant), while higher scores on the symptom and single-item scales indicate a higher level of symptoms (ie, a worse state of the participant).
Measured: Randomization up to approximately 53 months
TTD of Role Functioning Score as Measured by EORTC QLQ-C30
The EORTC QLQ-C30 is a questionnaire to assess quality of life of cancer patients, it is composed of 30 questions (items) resulting in 5 functional scales, 1 global health status scale, 3 symptom scales, and 6 single items. Scoring of the QLQ-C30 is performed according to QLQ-C30 Scoring manual. All of the scales and single-item measures range in score from 0 to 100. Higher score for the functioning scales and global health status denote a better level of functioning (ie, a better state of the participant), while higher scores on the symptom and single-item scales indicate a higher level of symptoms (ie, a worse state of the participant).
Measured: Randomization up to approximately 53 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 May 2022
- Study start25 Jul 2022
- Primary completionFeb 2027 (estimated)
- Study completionFeb 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Triple Negative Breast CancerStudies of the same condition, open and under way.
- More trials run by Gilead SciencesThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 443 participants (actual)
Sponsor and investigators
- Lead sponsor
- Gilead Sciences
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Merck Sharp & Dohme LLC
- Responsible party
- Sponsor
- Investigators
- Gilead Study Director, Study director, Gilead Sciences
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05382286
- Sponsor's protocol ID
- GS-US-592-6173
- Other IDs
- 2021-005742-14, KEYNOTE-D19, jRCT2041220123, MK-3475-D19, 2023-504194-21, 2023
- Acronym
- ASCENT-04
- Status last verified
- Sep 2025
- First submitted
- 16 May 2022
- Last updated
- 18 Sep 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Tolaney SM, de Azambuja E, Kalinsky K, Loi S, Kim SB, Yam C, Rapoport B, Im SA, Pistilli B, Mchayleh W, Cescon DW, Watanabe J, Banuelas MAL, Freitas-Junior R, Salvador Bofill J, Afshari M, Gary D, Wang L, Lai C, Schmid P; ASCENT-04/KEYNOTE-D19 Clinical Trial Investigators. Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer. N Engl J Med. 2026 Jan 22;394(4):354-366. doi: 10.1056/NEJMoa2508959.
PubMed 41564397
Study at a glance
From the registry record, last updated by the sponsor on 18 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1
- ClinicalTrials.gov ID
- NCT05382286
- Acronym / sponsor ID
- ASCENT-04 / GS-US-592-6173
- Conditions
- Triple Negative Breast Cancer, PD-L1 Positive
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 443 participants (actual)
- Lead sponsor
- Gilead SciencesIndustry (pharma, biotech, devices)
- Collaborators
- Merck Sharp & Dohme LLC
- Study start
- 25 Jul 2022 (actual)
- Primary completion
- Feb 2027 (estimated)
- Study completion
- Feb 2027 (estimated)
- First posted
- 19 May 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's choice (TPC) and pembrolizumab in participants with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors express programmed cell death ligand 1 (PD-L1).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Sacituzumab Govitecan-hziy (SG) + Pembrolizumab | Experimental | Drug: Sacituzumab Govitecan-hziy, Drug: PembrolizumabParticipants will receive SG 10 mg/kg on Days 1 and 8 of 21-day cycles and pembrolizumab 200 mg on Day 1 of 21-day cycles Pembrolizumab will be administered for a maximum of 35 cycles. |
| Pembrolizumab + Treatment of Physician's Choice (TPC) | Active comparator | Drug: Pembrolizumab, Drug: Paclitaxel, Drug: nab-Paclitaxel, Drug: Gemcitabine, Drug: CarboplatinParticipants will receive pembrolizumab 200 mg on Day 1 of each 21-day cycle (maximum 35 cycles) plus TPC determined prior to randomization from 1 of the 3 allowed regimens: * Paclitaxel 90 mg/m^2 on Days 1, 8, and 15 of 28-day cycles * nab-Paclitaxel 100 mg/m^2 on Days 1, 8, and 15 of 28-day cycles * Gemcitabine 1000 mg/m^2 + carboplatin area under the curve (AUC) 2 on Days 1 and 8 of 21-day cycles |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Individuals with locally advanced, inoperable, or metastatic triple-negative breast cancer (TNBC) who have not received previous systemic therapy for advanced disease and whose tumors are programmed cell death ligand 1 (PD-L1) positive at screening.
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
- Demonstrates adequate organ function
- Male and female individuals of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception.
- Individuals with HIV must be on antiretroviral therapy (ART) and have a well-controlled HIV infection/disease.
Key exclusion criteria (11 listed)
- Positive serum pregnancy test or women who are lactating.
- Received prior therapy with an agent directed to another stimulatory or coinhibitory T-cell receptor.
- Individuals may not have received systemic anticancer treatment (with the exception of endocrine therapy) within the previous 6 months or radiation therapy within 2 weeks prior to enrollment.
- Individuals may not be participating in a study with an investigational agent or investigational device within 4 weeks prior to randomization. Individuals participating in observational studies are eligible.
- Have previously received topoisomerase 1 inhibitors or antibody drug conjugates containing a topoisomerase inhibitor.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Sacituzumab Govitecan-hziyAlso: IMMU-132, Trodelvy™, GS-0132Administered intravenously | Drug | Sacituzumab Govitecan-hziy (SG) + Pembrolizumab |
| PembrolizumabAlso: KEYTRUDA®Administered intravenously | Drug | Pembrolizumab + Treatment of Physician's Choice (TPC), Sacituzumab Govitecan-hziy (SG) + Pembrolizumab |
| PaclitaxelAlso: Taxol®Administered intravenously | Drug | Pembrolizumab + Treatment of Physician's Choice (TPC) |
| nab-PaclitaxelAlso: Abraxane®Administered intravenously | Drug | Pembrolizumab + Treatment of Physician's Choice (TPC) |
| GemcitabineAlso: GemzarAdministered intravenously | Drug | Pembrolizumab + Treatment of Physician's Choice (TPC) |
| CarboplatinAdministered intravenously | Drug | Pembrolizumab + Treatment of Physician's Choice (TPC) |
Primary outcome
Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
Time frame: Randomization up to approximately 33 months
PFS is defined as the time from the date of randomization until the date of objective progressive disease (PD) or death (whichever comes first).
11 secondary outcomes
Overall Survival (OS)
Time frame: Randomization up to approximately 53 months
Objective Response Rate (ORR) as Assessed by BICR per RECIST Version 1.1
Time frame: Randomization up to approximately 53 months
Duration of Response (DOR) as Assessed by BICR per RECIST Version 1.1
Time frame: Randomization up to approximately 53 months
Time to Response (TTR) as Assessed by BICR per RECIST Version 1.1
Time frame: Randomization up to approximately 53 months
Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)
Time frame: First dose date up to 53 months plus 30 days
Percentage of Participants Experiencing Clinical Laboratory Abnormalities
Time frame: First dose date up to 53 months plus 30 days
Time to Deterioration (TTD) in Global Health Status/Quality of Life (QoL) Scale as Measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, Core Questionnaire, Version 3.0 (EORTC QLQ-C30)
Time frame: Randomization up to approximately 53 months
TTD of Pain Score as Measured by EORTC QLQ-C30
Time frame: Randomization up to approximately 53 months
TTD of Fatigue Score as Measured by EORTC QLQ-C30
Time frame: Randomization up to approximately 53 months
TTD of Physical Functioning Domain Score as Measured by EORTC QLQ-C30
Time frame: Randomization up to approximately 53 months
TTD of Role Functioning Score as Measured by EORTC QLQ-C30
Time frame: Randomization up to approximately 53 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Sep 2025.
- Derived from this study: PubMed 41564397Tolaney SM, de Azambuja E, Kalinsky K, Loi S, Kim SB, Yam C, Rapoport B, Im SA, Pistilli B, Mchayleh W, Cescon DW, Watanabe J, Banuelas MAL, Freitas-Junior R, Salvador Bofill J, Afshari M, Gary D, Wang L, Lai C, Schmid P; ASCENT-04/KEYNOTE-D19 Clinical Trial Investigators. Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer. N Engl J Med. 2026 Jan 22;394(4):354-366. doi: 10.1056/NEJMoa2508959.
- Gilead Clinical Trials WebsiteLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Triple Negative Breast Cancer
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 2
BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC
Triple-Negative Breast Cancer (TNBC), Brain Metastases
Active, not recruitingPhase 1/2
Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...
Colorectal Neoplasms, Breast Neoplasms
RecruitingPhase 2
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Breast Neoplasms, Breast Cancer
RecruitingObservational study
Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases
Breast Cancer, Breast Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Gilead Study Director study director
Gilead Sciences
504 sites in 28 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Sacituzumab Govitecan-hziy, Pembrolizumab and Paclitaxel in people with Triple Negative Breast Cancer and PD-L1 Positive, run by Gilead Sciences at 504 sites in 28 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 18 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 504 sites in United States, Japan, Italy, Germany, Spain and 23 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (time frame: Randomization up to approximately 33 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05382286, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Sep 2025.